Technique to monitor drug delivery noninvasively in vivo

• US 6,468,505 B1
• Filed: 10/24/2000
• Issued: 10/22/2002
• Est. Priority Date: 04/09/1997
• Status: Expired due to Fees

• Current Assignee: Philipp Lang
• Original Assignee: Philipp Lang
• Inventors: Lang, Philipp, Saeed, Maythem, Wendland, Michael F., Meyer, Olivier
• Primary Examiner(s): Hartley, Michael G.
• Application Number:
  US09/696,352
• Time in Patent Office: 728 Days
• Field of Search: 424/9.321, 424/9.3, 424/9.36, 424/450
• US Class Current: 424/9.321
• CPC Class Codes: A61K 49/1812 liposomes, polymersomes, e.g. immunoliposomes

Abstract

The present invention relates to the field of diagnostic imaging and more specifically to the field of monitoring drug delivery using non-invasive imaging techniques. The present invention provides for imaging agents and compositions useful for NMR, computed tomography, scintigraphy, PET and any other type of imaging where the imaging agent can be carried by liposomes or other lipid based vehicles, such as micelles or suspended lipid aggregates.

Claims

1. A composition for NMR imaging during drug delivery, comprising:

a) a paramagnetic chelate with a paramagnetic ion and in amount sufficient to enhance NMR imaging,

b) a liposome comprising a bilayer and an interior volume and in an amount sufficient to permit delivery of said liposome to a tissue, wherein said liposome carries said paramagnetic chelate,

c) a polyalkylether associated with said liposome, and

d) a therapeutic agent in a therapeutic amount, wherein liposome carries said therapeutic agent.

2. The composition of claim 1, wherein said paramagnetic chelate is selected from the group consisting of BOTPA, EHPG, DPDP, DTPA, DOA3 and HBED.

3. The composition of claim 1, wherein said polyalkylether is poly(ethylene glycol).

4. The composition of claim 3 wherein said liposome has an average size distribution selected from the group consisting of 85, 110, 135, and 150 nanometers in diameter.

5. The composition of claim 4, wherein said liposome comprises a molecule selected from the group consisting of phosphatidyl ethanolamine, phosphatidyl choline, dipalmitoyl phosphatidic acid, cholesterol and alpha-tocopherol.

6. The composition of claim 5, wherein said poly(ethylene glycol) is present in the amount 1 to 25 mole percent of total lipid content.

7. The composition of claim 6, wherein said interior volume has a pH of 6.5 to 7.5.

8. The composition of claim 6, wherein said tissue is a solid tumor in a non-reticuloendothelial organ.

9. The composition of claim 3, wherein said therapeutic agent is selected from the group consisting of an oligonucleotide, nucleic acid, peptide, and antibody.

10. The composition of claim 3, wherein said therapeutic agent is selected from the group consisting of a compound having a molecular weight of less than 1500 grams per mole and a low permeability to said liposome, and a compound having a molecular weight of less than 1500 grams per mole and lipophilic for said bilayer.

11. The composition of claim 10, wherein said compound has EC50 of less than 1 micromolar for inhibiting proliferation of a cancer cell in vitro and said composition is contained in a syringe or catheter.

12. The composition of claim 3, wherein said compound is selected from the group consisting of anticancer agents, chemotherapeutic agents, antiinflammatory agents, antiinfectious agents, gene therapy agents, antisense oligonucleotides, ribozymes, and antiviral agents.

13. A method of drug delivery in a mammal, comprising:

a) administering to a mammal in need thereof a composition, comprising;

i) a paramagnetic chelate with a paramagnetic ion and in amount sufficient to enhance NMR imaging,

ii) a liposome comprising a bilayer and an interior volume and in an amount sufficient to permit delivery of said liposome to a tissue, wherein said liposome carries said paramagnetic chelate,

iii) a polyalkylether associated with said liposome, and

iv) a therapeutic agent in a therapeutic amount, wherein said liposome carries said therapeutic agent, whereby drug delivery is achieved.

14. The method of claim 13, wherein said mammal is a human suspected of having a proliferation of a cellular mass.

15. The method of claim 14, wherein said polyalkylether is poly(ethylene glycol).

16. The method of claim 14, wherein said composition is administered using a device selected from the group consisting of a intravenous syringe injection, a catheter, an intravenous drip and an intraperitoneal syringe injection.

17. The method of claim 14, wherein said composition is administered at a dose of 0.05 to 2 millimole of lipid per kilogram of body weight.

18. A method of monitoring drug delivery in a mammal, comprising:

a) administering to a mammal need thereof a composition, comprising;

i) an imaging agent and in amount sufficient to enhance NMR imaging,

ii) a liposome comprising a bilayer and an interior volume and in an amount sufficient to permit delivery of said liposome to a tissue, wherein said liposome carries said imaging agent and said liposome enhances imaging compared to the absence of said imaging agent and said liposome selectively distributes said imaging agent to a tumor tissue compared to a non-tumor tissue,

iii) a polyalkylether associated with said liposome, and

iv) a therapeutic agent in an therapeutic amount, wherein said liposome carries said therapeutic agent, and

b) imaging a tissue of said mammal, wherein drug delivery can be monitored.

19. The method of claim 18, wherein said imaging is quantitative and amount of said liposome delivered to said tissue can be calculated and optionally determining a volume of said tissue to monitor as an indication of tissue proliferation or a reduction in tissue mass.

20. The method of claim 18, wherein said liposome further comprises a tissue specific antibody.

21. The method of claim 18, wherein said imaging comprises imaging at a time selected from the group consisting of at least 10 hours post injection, at least 24 hours post injection, at least 48 hours post injection, at least 72 hours post injection, and at least 96 hours post injection.